(Total Views: 210)
Posted On: 02/13/2024 4:49:26 PM
Post# of 94
NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head of business development and sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as marketing and commercial excellence lead for cell and gene therapies for Central, Southern and Eastern Europe. “I am pleased to welcome Liat to Scinai,” said Amir Reichman, Scinai’s CEO. “Her pharmaceutical sales, marketing and leadership experience, in particular in Israel and Europe, align with our strategic decision to grow Scinai Bioservices CDMO into a trusted provider of drug development services, including for preclinical and clinical trials and GMP manufacturing for clinical supplies.”
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head of business development and sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as marketing and commercial excellence lead for cell and gene therapies for Central, Southern and Eastern Europe. “I am pleased to welcome Liat to Scinai,” said Amir Reichman, Scinai’s CEO. “Her pharmaceutical sales, marketing and leadership experience, in particular in Israel and Europe, align with our strategic decision to grow Scinai Bioservices CDMO into a trusted provider of drug development services, including for preclinical and clinical trials and GMP manufacturing for clinical supplies.”
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
